News Results for Mporium Group (MPM)

Charles Pendred, Chairman, bought 2,000,000 shares in the company on the 29th July 2019 at a price of 1.01p. The Director now holds 9,300,000 shares. NOTE: PCA Story provided by...

Marketing company Mporium Group said its annual losses doubled after its revenue more than halved. Pre-tax losses for the year through December amounted to £7.7m, compared to losses of £3.9m...

Marketing technology company Mporium Group said it had raised £1.9m from a share issue to help it restructure the business and provide working capital. New shares in the company were issued at 1p...

Marketing company Mporium Group warned it would miss its earnings guidance and had raised £1.5m via a share issue to fund a business restructure. New shares in the company were issued at 1p each....

finnCap today initiates coverage of Mporium Group Plc (LON:MPM) with a corporate investment rating and price target of 8p. Story provided by StockMarketWire.com Broker Forecasts data provided by...

Markeing company Mporium Group said it had expanded a commercial agreement announced in February with a 'leading global sports media business'. Under the updated terms, Mporium's sports syncing...

Marketing technology provider Mporium Group said it had signed an agreement to provide its technology to a recruitment company that it didn't name. The client was 'one of the world's top five...

Marketing services provider Mporium Group said it had substantially boosted its revenue following the signing of an agreement with consumer regulation group Allay. Mporium had taken on...

Marketing firm Mporium Group said it had signed a supply agreement with a global sports media business that it didn't name. This new direct-to-brand agreement represented a major milestone for the...

Marketing technology company Mporium Group said it had signed a strategic collaboration agreement with claims management specialist Allay. The company said it would be an exclusive supplier to...

Event-driven marketing company Mporium Group said it had launched a new trading division, to be lead by Thomas J Smith. The MporiumX division would run digital advertising campaigns on a...

Marketing company Mporium said it had raised around £2.3m from a share issue to provide working capital and 'support the continued momentum of the business'. New shares in the company were issued...

Nelius De Groot, Chief Executive Officer, bought 750,000 shares in the company on the 30th August 2018 at a price of 6.10p. The Director now holds 10,027,633 shares. Story provided by...

Marketing firm Mporium Group said it had signed an agreement to provide its demand analysis products to one of the world's largest media-services networks. The network provided services to over...

Marketing technology company Mporium Group said its technology was used during the Samsung S9 phone launch campaign, as well as being part of further, ongoing campaigns for the Korean electronics...

Marketing company Mporium Group said annual losses narrowed as revenue ticked up. Pre-tax losses amounted to £3.9m, compared to £4.8m of red ink a year earlier. Revenue rose to £2.0m, from £1.8m....

Nicholas Bertolotti, Non Executive Director, bought 425,170 shares in the company on the 23rd February 2018 at a price of 8.23p. The Director now holds 425,170 shares. Story provided by...

Mporium Group said it had appointed Nicholas Bertolotti as a new non-executive director. Bertolotti was previously a managing director in investment banking at Credit Suisse and had also worked at...

Barry Moat, Chairman, bought 275,000 shares in the company on the 14th February 2018 at a price of 7.00p. The Director now holds 10,412,196 shares. Story provided by StockMarketWire.com Director...

Nelius De Groot, Chief Executive Officer, bought 275,000 shares in the company on the 15th February 2018 at a price of 7.00p. The Director now holds 9,277,633 shares. Story provided by...

Mporium Group has signed a commercial agreement for its technology services with media investment management company GroupM UK. The agreement provides access to Mporium's Impact technology across...

Further to the announcement made on 20 December 2017, Mporium raised £3.2m through the successful subscription of 53,333,333 new ordinary shares of 0.5p each in the capital of the company at an...

Mporium has announced that it is considering a private subscription for new ordinary shares by certain current investors within the Group's existing pre-emptive authorities. Mporium also confirmed...

Mporium Group has agreed to provide technology products to what it said was one of the world's largest performance marketing agencies. The agency, which it didn't name, operates in more than 50...

Mporium, a technology firm delivering event-driven marketing, has appointed Aleksander Ohrn as chief technology officer (CTO). Ohrn was most recently the co-founder and CTO of Cxense, a position...

Advertising technology company mporium (MPM) reduced its operating loss by 18% to £2.4 million in the first half as revenues rose by 21% to £1.1 million. Growth was driven by an increase in...

Story provided by StockMarketWire.com

mporium has confirmed that, at the Annual General Meeting held earlier today, all resolutions proposed were duly passed. At 2:12pm: (LON:MPM) Mporium Group Plc share price was 0p at 13.38p...

mporium has reduced its FY pretax loss from continuing operations to £4.8m, from a loss of £5.1m a year previously. Revenue was £1.8m, from £1.3m. CEO Barry Moat said 2016 was a very successfully...

Story provided by StockMarketWire.com

mporium Group has raised about £3.05m gross via a placing of 20.33m shares at 15p each. Story provided by StockMarketWire.com

Story provided by StockMarketWire.com

mporium Group announces a commercial agreement to provide its IMPACT technology product to Essence, a global digital agency that is majority owned by WPP. This new agreement follows the...

Story provided by StockMarketWire.com

Story provided by StockMarketWire.com

Barry Moat, Chief Executive Officer, bought 230,000 shares in the company on the 26th September 2016 at a price of 6.50p. The Director now holds 10,137,196 shares. Story provided by...

Nigel Walder, Chairman, bought 139,715 shares in the company on the 9th September 2016 at a price of 7.25p. The Director now holds 8,451,943 shares. Story provided by StockMarketWire.com...

Aidan Casey, Non Executive Director, bought 49,793 shares in the company on the 9th September 2016 at a price of 7.25p. The Director now holds 4,111,355 shares. Story provided by...

Barry Moat, Chief Executive Officer, bought 200,000 shares in the company on the 9th September 2016 at a price of 7.00p. The Director now holds 9,907,196 shares. Story provided by...

Barry Moat, Chief Executive Officer, bought 28,500 shares in the company on the 8th September 2016 at a price of 7.00p. The Director now holds 9,707,196 shares. Story provided by...

mporium Group's overall revenue increased to £870,473 in the six months to the end of June (2015: £559,065). The loss from ordinary activities before taxation fell £2,939,919 from £3,895,937. At...

Barry Moat, Chief Executive Officer, bought 175,000 shares in the company on the 14th July 2016 at a price of 7.75p. The Director now holds 9,422,196 shares. Story provided by...

mporium Group, the mobile commerce specialist, has raised approximately £3.1 million before expenses through a placing of 41,379,008 ordinary shares at 7.5p apiece. The proceeds will be used to...

Barry Moat, Chief Executive Officer, bought 356,071 shares in the company on the 3rd June 2016 at a price of 7.00p. The Director now holds 8,929,196 shares. Story provided by StockMarketWire.com...

Barry Moat, Chief Executive Officer, bought 623,125 shares in the company on the 21st April 2016 at a price of 8.00p. The Director now holds 8,573,125 shares. Story provided by...

Richard Gordon, Financial Director, bought 99,702 shares in the company on the 21st April 2016 at a price of 8.00p. The Director now holds 1,199,702 shares. Story provided by StockMarketWire.com...

Aidan Casey, Non Executive Director, bought 311,562 shares in the company on the 21st April 2016 at a price of 8.00p. The Director now holds 4,061,562 shares. Story provided by...

mporium Group, the mobile commerce specialist, has announced the appointment of Aidan Casey as a non-Executive Director of the Company with immediate effect. At 12:13pm: (LON:MPM) Mporium Group...

mporium Group has recorded an operating loss for the year to December, after excluding share based payments, of GBP3.9m (2014: GBP4.8m). The total comprehensive loss for the year was GBP4.9m (2014:...

Nigel Walder, Chairman, bought 102,154 shares in the company on the 17th February 2016 at a price of 9.75p. The Director now holds 8,312,228 shares. Story provided by StockMarketWire.com...

mporium Group has raised about GBP3.1m gross via a placing of 38.4m shares at 8p each. The funds were raised from a combination of new and existing shareholders. Proceeds of the issue would be used...

Story provided by StockMarketWire.com

Nigel Walder, Chairman, bought 1,538,460 shares in the company on the 9th October 2015 at a price of 6.50p. The Director now holds 8,088,460 shares. Story provided by StockMarketWire.com...

Richard Gordon, Financial Director, bought 100,000 shares in the company on the 2nd October 2015 at a price of 6.13p. The Director now holds 1,100,000 shares. Story provided by...

Barry Moat, Chief Executive Officer, bought 800,000 shares in the company on the 2nd October 2015 at a price of 6.13p. The Director now holds 7,950,000 shares. Story provided by...

Nigel Walder, Chairman, bought 400,000 shares in the company on the 2nd October 2015 at a price of 6.13p. The Director now holds 6,550,000 shares. Story provided by StockMarketWire.com Director...

Story provided by StockMarketWire.com

mporium says Cxense has received authority from its shareholders to issue and allot 51,177 new shares to the company under the proposed share swap announced on 2 June. mporium says its...

Proximagen Neuroscience had yesterday (Mar 4) received a 91.26% take-up of its recommended offer for Minster Pharmaceuticals. Cancellation of AIM trading in Minster's shares is expected on...

Proximagen Neuroscience had received valid acceptances representing about 86.25% of the share capital of Minster Pharmaceuticals yesterday (Feb 16), the first closing date of its recommended...

Drug developer Minster Pharmaceuticals narrowed its first-half pre-tax loss to £0.93m from the previous £3.63m. The company, which focuses on neurological and psychiatric disorders, said the...

Story provided by Business Financial Newswire

Minster Pharmaceuticals says that Robert Aubrey will relinquish executive responsibilities with effect from 30 September 2009 to become a Non-executive Director. Story provided by Business...

Minster Pharmaceuticals has filed a US patent application covering a therapy using sabcomeline to treat a psychotic disorder. The company says that based on an opinion from its US attorney, it is...

Karl Keegan, Financial Director bought 151,900 shares in the company on the 17th July 2009 at a price of 6.50p. The Director now holds 151,900 shares representing 0.26% of the shares in issue....

Minster Pharmaceuticals, the AIM quoted drug development company, has announced that The Lancet Neurology, a peer-reviewed journal, has published positive results from a Phase 11 trial of tonabesat...

Karl Keegan has been appointed as chief financial officer of drug development company Minster Pharmaceuticals. He succeeds Robert Aubrey, who will continue as an executive director. Dr Keegan,...

Minster Pharmaceuticals chief executive Paul Sharpe is stepping down after eight years in the job. He will remain as a non-executive director. Chairman John Russell is taking over as interim CEO...

Drug development company Minster Pharmaceuticals has announced that its migraine prevention compound tonabersat has failed to produce positive results in a a Phase IIb study. Minster says...

Minster Pharmaceuticals recorded a post-tax loss of £3.48m for the half-year to end-September, reflecting on-going investment in its TEMPUS study The 500-patient Phase IIb TEMPUS study in North...

Minster Pharmaceuticals said today that its current year has 'begun well'. The company reported progress in clinical studies, formation of new scientific collaborations and acquisition of rights...